Incidence and Risk of Hypertension and Proteinuria in Cancer Patients Treated with Lenvatinib: A Systematic Review and Meta-analysis
A partir d'une revue systématique de la littérature (64 études, 10 443 patients), cette méta-analyse évalue le risque d'hypertension et de protéinurie associé à une utilisation de lenvatinib chez les patients atteints d'un cancer
Background: Published data regarding the overall risks and incidence of hypertension and proteinuria associated with lenvatinib remain unclear.
Methods: We performed a systematic review and meta-analysis to quantify the precise risks and incidence of lenvatinib-associated hypertension and proteinuria. We systematically searched PubMed, Cochrane Library, and Web of Science databases for studies on the incidence of hypertension and proteinuria, which were published until April 24, 2023.
Results: A total of 10,443 patients were included in the 64 studies identified from the literature. The incidence of all-grade and grade ≥3 hypertension was 50% (95% confidence interval [CI]: 43–58%) and 14% (95% CI: 10–18%) for patients treated with lenvatinib. The incidence of all-grade and grade ≥3 proteinuria was 32% (95% CI: 26–38%) and 6% (95% CI: 4–7%), respectively. Compared with controls, lenvatinib significantly increased the risk of all-grade hypertension (odds ratio [OR]: 2.4, 95% CI: 1.4 − 4.1), grade ≥3 hypertension (OR: 2.7, 95% CI: 1.2 − 6.0), all-grade proteinuria (OR: 3.5, 95% CI: 1.9 − 6.6), and grade ≥3 proteinuria (OR: 2.85, 95% CI: 1.5 − 5.3). Compared to low-dose lenvatinib (≤12 mg/day), high-dose lenvatinib (≥20 mg/day) treatment significantly increased the risks of all-grade hypertension (OR: 4.7, 95% CI: 4.2 − 5.2), grade ≥3 hypertension (OR: 7.7, 95% CI: 6.8 − 8.7), all-grade proteinuria (OR: 1.8, 95% CI: 1.6 − 2.0), and grade ≥3 proteinuria (OR: 1.7, 95% CI: 1.5 − 2.1).
Conclusion: Our review revealed that lenvatinib treatment increases the risks of hypertension and proteinuria, particularly with high-dose lenvatinib.
The Oncologist , résumé, 2025